Sex differences in adverse drug reactions from Adalimumab and etanercept in patients with inflammatory rheumatic diseases.

Helen R Gosselt,Jette A van Lint,Leanne J Kosse,Phyllis I Spuls,Harald E Vonkeman,Sander W Tas,Frank Hoentjen,Michael T Nurmohamed,Bart J F van den Bemt,Martijn B A van Doorn,Naomi T Jessurun

Expert opinion on drug safety（2023）

引用 0|浏览35

暂无评分

摘要

Sex differences in the frequency and nature of ADRs, but not in ADR burden, exist during treatment with adalimumab and etanercept in patients with inflammatory rheumatic diseases. This should be taken into consideration when investigating and reporting results on ADRs and when counseling patients in daily clinical practice.

查看译文

关键词

ADRs,Sex differences,biologics,burden,patient-reported outcomes (PRO)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要